Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
ARMP Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 20, 2026
Report Source: 2026 1st Quarter Report
Armata Pharmaceuticals Inc. Stock Analysis ARMP
United States Health Care Micro Cap Report: Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Los Angeles, California and currently employs 61 full-time employees. The firm is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. The company is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
Read More Armata Pharmaceuticals Inc (ARMP) Chart
Key Statistics of Armata Pharmaceuticals Inc (ARMP)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$7.25Volume
141.26KP/E Ratio (TTM)
-52 Week Range
Market Cap
302.13MAvg. Volume
66.28KDividend Yield
-Financial Metrics & Statements of Armata Pharmaceuticals Inc (ARMP)
FAQ's for Armata Pharmaceuticals Inc (ARMP)
- According to Musaffa’s Shariah screening methodology, Armata Pharmaceuticals Inc (ARMP) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Armata Pharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Armata Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Armata Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Armata Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Armata Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.